Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bert M Klebl

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|February 13, 2004
Stacking up the armory against virusesBert M Klebl
Drug Discovery Today. Technologies|July 2, 2014
Chemical kinomics - a target gene family approach in chemical biologyBert M Klebl
Expert Opinion on Investigational Drugs|April 19, 2005
Advances in anti-viral therapeuticsBert M Klebl
Expert Opinion on Therapeutic Targets|September 28, 2005
Second-generation kinase inhibitorsBert M Klebl, Gerhard Müller
Antiviral Chemistry & Chemotherapy|May 14, 2005
Host cell targets in HCV therapy: novel strategy or proven practice?Bert M Klebl, Alexander Kurtenbach, Kostas Salassidis, et al.
SLAS Discovery : Advancing Life Sciences R & D|November 7, 2024
Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZBlaž Andlovic, Alexander Wolf, Malgorzata Hiltmann, et al.
Cancers|September 23, 2022
White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer TherapyEdgar Dahl, Sophia Villwock, Peter Habenberger, et al.
Assay and Drug Development Technologies|July 30, 2010
A flexible multiwell format for immunofluorescence screening microscopy of small-molecule inhibitorsAnne-Kathrin Scholz, Bert M Klebl, Markus Morkel, et al.
RNA (New York, N.Y.)|January 31, 2008
An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitroGünter Mayer, Bernhard Wulffen, Christian Huber, et al.
European Journal of Medicinal Chemistry|December 23, 2023
Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from FlatlandFrithjof Bjørnstad, Simen Havik, Thomas Ihle Aarhus, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|February 13, 2004
Stacking up the armory against virusesBert M Klebl
Drug Discovery Today. Technologies|July 2, 2014
Chemical kinomics - a target gene family approach in chemical biologyBert M Klebl
Expert Opinion on Investigational Drugs|April 19, 2005
Advances in anti-viral therapeuticsBert M Klebl
Expert Opinion on Therapeutic Targets|September 28, 2005
Second-generation kinase inhibitorsBert M Klebl, Gerhard Müller
Antiviral Chemistry & Chemotherapy|May 14, 2005
Host cell targets in HCV therapy: novel strategy or proven practice?Bert M Klebl, Alexander Kurtenbach, Kostas Salassidis, et al.
SLAS Discovery : Advancing Life Sciences R & D|November 7, 2024
Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZBlaž Andlovic, Alexander Wolf, Malgorzata Hiltmann, et al.
Cancers|September 23, 2022
White Paper: Mimetics of Class 2 Tumor Suppressor Proteins as Novel Drug Candidates for Personalized Cancer TherapyEdgar Dahl, Sophia Villwock, Peter Habenberger, et al.
Assay and Drug Development Technologies|July 30, 2010
A flexible multiwell format for immunofluorescence screening microscopy of small-molecule inhibitorsAnne-Kathrin Scholz, Bert M Klebl, Markus Morkel, et al.
RNA (New York, N.Y.)|January 31, 2008
An RNA molecule that specifically inhibits G-protein-coupled receptor kinase 2 in vitroGünter Mayer, Bernhard Wulffen, Christian Huber, et al.
European Journal of Medicinal Chemistry|December 23, 2023
Pyrrolopyrimidine based CSF1R inhibitors: Attempted departure from FlatlandFrithjof Bjørnstad, Simen Havik, Thomas Ihle Aarhus, et al.
Pageof 2